Comparison of QT Interval Readings Between Smartwatch Combined With Cardiologs Artificial Intelligence and 12-lead ECG

Atrial Fibrillation Clinical Trial

Official title:

Comparison of QT Interval Readings Between Smartwatch Combined With Cardiologs Artificial Intelligence and 12-lead ECG in Subjects Hospitalized for Antiarrhythmic Drug Initiation and Follow-up

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05161065
• Other study ID #: WatchQT
• Status: Completed
• Start date: February 12, 2022
• Est. completion date: February 28, 2023

Study information

• Verified date: October 2023
• Source: Cardiologs Technologies
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The WatchQT study will compare the performance of a smartwatch combined with Cardiologs ECG AI Analysis system in monitoring corrected QT (QTc) intervals with that measured on a manually read 12-lead ECG in subjects with Normal Sinus Rhythm (NSR) during antiarrhythmic drug (AAD) initiation and follow-up at the hospital.

Description:

The WatchQT Study is a prospective, non-significant risk, non-randomized, monocentric, open, comparative, concordance pilot study.

Under subject consent, subjects hospitalized for AAD initiation and monitoring will have smartwatch ECG recordings done simultaneously with 12-lead ECG measurements before and after drug administration twice a day, in accordance with the existing in-stay subject monitoring protocol.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 50
• Est. completion date: February 28, 2023
• Est. primary completion date: February 28, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 22 Years and older

Eligibility

Inclusion Criteria:

1. Subjects over 22, able and willing to participate in the study

2. Subjects who are admitted to the hospital in NSR or AF and are eligible for AAD (class Ia or class III) dose initiation or re-initiation.

3. Subjects having read the patient information letter and provided his/her consent to participate in writing, by dating and signing the informed consent prior to any trial-related procedure being conducted

Exclusion Criteria:

1. Subjects with Cardiac Implantable Electronic Devices (CIED)

2. Pregnant or breast-feeding subjects

Related Conditions & MeSH terms

• Atrial Fibrillation

Intervention

Device:
• Cardiologs
Apple Watch recordings interpreted by Cardiologs AI done simultaneously with each 12-lead ECG

Locations

Country	Name	City	State
United States	Massachusetts General Hospital	Boston	Massachusetts

Sponsors (1)

Lead Sponsor	Collaborator
Cardiologs Technologies

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Concordance between QTc intervals (in ms) measured by smartwatch combined with Cardiologs AI and that measured by manually read 12-lead ECG	Concordance between QTc intervals measured by smartwatch combined with Cardiologs AI and that measured by manually read 12-lead ECG for each measurement done during NSR. The Bazett (QTcB in ms) and Fridericia (QTcF in ms) methods will be used to correct QT intervals	Readings taken simultaneously right before and 2-3 hours after drug administration during hospitalization
Secondary	Description of the sensitivity and specificity of the smartwatch combined with Cardiologs AI	Description of the sensitivity and specificity of the smartwatch combined with Cardiologs AI in determining subjects at risk of AAD induced ventricular arrhythmia compared to that identified by manually read 12-lead ECG in subjects with a prolonged QTc > 500 ms and/or subjects with a QTc prolongation of > 15% after their initial AAD dose	Readings taken simultaneously right before and 2-3 hours after drug administration during hospitalization
Secondary	Concordance between QTcB and QTcF intervals measured by the different methods	Concordance between QTcB and QTcF intervals measured by the different methods (smartwatch combined with Cardiologs AI, smartwatch read manually, 12-lead read manually, lead 1 from 12-lead read manually and automated interpretation of the 12 lead ECG machine)	Readings taken simultaneously right before and 2-3 hours after drug administration during hospitalization
Secondary	Description of the QTc interval measurements in NSR	Description of the QTc interval measurements in NSR as a function of timepoints by the different methods	Readings taken simultaneously right before and 2-3 hours after drug administration during hospitalization
Secondary	Quantitative analysis to determine the interobserver variability	Quantitative analysis to determine the interobserver variability in QTc interval measurements by the smartwatch and 12-lead ECG manual readings	Readings taken simultaneously right before and 2-3 hours after drug administration during hospitalization
Secondary	Description of the QT interval defined as uncertain by the smartwatch combined with Cardiologs AI	Description of the QT interval defined as uncertain by the smartwatch combined with Cardiologs AI	Readings taken simultaneously right before and 2-3 hours after drug administration during hospitalization
Secondary	Descriptive analysis of QT interval measurements in AF measured by smartwatch combined with Cardiologs AI and manually read 12-lead ECG	.Descriptive analysis of QT interval measurements in AF measured by smartwatch combined with Cardiologs AI and manually read 12-lead ECG at each timepoint and overall.	Readings taken simultaneously right before and 2-3 hours after drug administration during hospitalization
Secondary	Analysis of QT interval measured in subsets of subjects with and without wide QRS	Patient with wide QRS is determined as a QRS>120ms at D0 from automated interpretation of the 12-lead ECG machine. The analysis will be done in subset of 2 groups according to the QRS measured as wide or not machine	Readings taken simultaneously right before and 2-3 hours after drug administration during hospitalization